Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
Source abstract
Abstract
Aims: The present study was performed to investigate the efficacy and safety of anti-programmed death-1 (PD-1)/programmed death-ligand-1 (PD-L1) treatments in non-small cell lung cancer (NSCLC).Methods: The potential articles were searched from Pubmed and Embase. The end points included overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and adverse events. p < .05 or I2 ≥ 50% meant obvious heterogeneity, and the random-effects model was adopted for pooled analysis, otherwise, the fixed-effects model was used. Subgroup analysis was performed based on the treatment line. Potential publication bias was tested with Begg's funnel plot.Results: Eight eligible articles were included. OS rate of NSCLC patients was prolonged by anti-PD-1/PD-L1 treatments (HR = 0.685, 95%CI = 0.632-0.742), as well as PFS (HR = 0.821, 95%CI = 0.721-0.936). Meanwhile, anti-PD-1/PD-L1 treatments could greatly enhance the ORR (RR = 1.646, 95%CI = 1.382-1.961), with fewer adverse events (RR = 0.800, 95%CI = 0.688-0.931). Subgroup analysis indicated that anti-PD-1/PD-L1 treatments as second-line treatment could significantly improve the survival of patients without adverse events. The overall results were robust, without significant publication bias (p = .532).Conclusion: Anti-PD-1/PD-L1 treatments show better clinical efficacy and higher safety than chemotherapy in NSCLC.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cancer Immunotherapy and Biomarkers · Lung Cancer Treatments and Mutations · Colorectal and Anal Carcinomas
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Oncology and Southwest Cancer Center, Southwest Hospital, Army Medical University
References (42)
Show source-provided references
1. 10.1634/theoncologist.13-S1-510.1634/theoncologist.13-S1-5 ↗
2. 10.1056/NEJMoa01195410.1056/NEJMoa011954 ↗
3. 10.1200/JCO.2004.08.16310.1200/JCO.2004.08.163 ↗
4. 10.1200/JCO.2000.18.10.209510.1200/JCO.2000.18.10.2095 ↗
5. 10.1038/nm73010.1038/nm730 ↗
6. 10.1126/science.271.5256.173410.1126/science.271.5256.1734 ↗
7. 10.1038/nrc323910.1038/nrc3239 ↗
8. 10.1016/j.ccell.2015.03.00110.1016/j.ccell.2015.03.001 ↗
9. 10.1056/NEJMoa100346610.1056/NEJMoa1003466 ↗
10. 10.1056/NEJMe120594310.1056/NEJMe1205943 ↗
11. 10.1056/NEJMoa120069010.1056/NEJMoa1200690 ↗
12. 10.1200/JCO.2014.59.435810.1200/JCO.2014.59.4358 ↗
13. 10.1016/S0140-6736(16)32517-X10.1016/S0140-6736(16)32517-X ↗
14. 10.1016/S0140-6736(15)01281-710.1016/S0140-6736(15)01281-7 ↗
15. 10.1016/S0140-6736(16)00587-010.1016/S0140-6736(16)00587-0 ↗
16. 10.1056/NEJMoa150462710.1056/NEJMoa1504627 ↗
17. 10.1056/NEJMoa150764310.1056/NEJMoa1507643 ↗
18. 10.1586/14737140.2016.112776010.1586/14737140.2016.1127760 ↗
19. 10.1056/NEJMoa160677410.1056/NEJMoa1606774 ↗
20. 10.1200/jco.2015.33.15_suppl.801010.1200/jco.2015.33.15_suppl.8010 ↗
21. 10.1056/NEJMoa06188410.1056/NEJMoa061884 ↗
22. 10.1200/JCO.2012.47.962610.1200/JCO.2012.47.9626 ↗
23. 10.1200/JCO.2007.14.546610.1200/JCO.2007.14.5466 ↗
24. 10.1200/JCO.2012.47.110210.1200/JCO.2012.47.1102 ↗
25. 10.1200/JCO.2000.18.12.235410.1200/JCO.2000.18.12.2354 ↗
26. 10.1016/S1470-2045(13)70310-310.1016/S1470-2045(13)70310-3 ↗
27. 10.1056/NEJMoa110462110.1056/NEJMoa1104621 ↗
28. 10.1056/NEJMoa141208210.1056/NEJMoa1412082 ↗
29. 10.1056/NEJMoa151066510.1056/NEJMoa1510665 ↗
30. 10.1056/NEJMoa141108710.1056/NEJMoa1411087 ↗
31. 10.1177/03008916120980061210.1177/030089161209800612 ↗
32. 10.1038/labinvest.2013.13010.1038/labinvest.2013.130 ↗
33. 10.1200/JCO.2009.26.760910.1200/JCO.2009.26.7609 ↗
34. 10.1158/2326-6066.CIR-14-004010.1158/2326-6066.CIR-14-0040 ↗
35. 10.1038/nature1401110.1038/nature14011 ↗
36. 10.1038/nature1390410.1038/nature13904 ↗
37. 10.1158/1078-0432.CCR-12-136210.1158/1078-0432.CCR-12-1362 ↗
38. 10.4049/jimmunol.110005610.4049/jimmunol.1100056 ↗
39. 10.1016/j.immuni.2007.05.01610.1016/j.immuni.2007.05.016 ↗
40. 10.1056/NEJMoa150182410.1056/NEJMoa1501824 ↗
41. 10.1097/MD.000000000000461110.1097/MD.0000000000004611 ↗
42. 10.1016/j.critrevonc.2016.02.00110.1016/j.critrevonc.2016.02.001 ↗